肝细胞肝癌的CT及MR比较影像学分析
|
摘要
目的:本研究通过非酒精性脂肪肝背景下的肝细胞肝癌(HCC)的CT及MR扫描,对化学位移T1WI双回波成像进行定量评估,并与CT所见对比;并总结在脂肪肝背景下肝细胞肝癌的T1WI表现特征。
材料与方法:2008年6月至2009年2月,对临床疑似或HCC高危人群行多排螺旋CT及3-T MR扫描,排除脂肪肝以外的肝脏背景异常后,共46例HCC患者纳入本研究,其中男性39例,女性7例,年龄35-76岁(平均50.53岁)。本研究患者被分为两组:非酒精性脂肪肝组(11例)和肝脏背景无异常组(35例)。所有患者有完整的多排螺旋平扫图像、MR化学位移T1WI正反相位图像,以及完整的临床资料。对CT及MR诊断脂肪肝进行一致性检验,并采用AFROC曲线分析,对比CT及T1WI双回波图像定量评估脂肪肝背景的效能,并对比不同肝脏背景下HCC病灶的对比噪声比(CNR)变化特征。
结果:1、所有46例患者中,在评估脂肪肝程度方面,T1WI双回波肝脏信号强度指数的大小与CT扫描的肝、脾CT值之比呈显著负相关关系,相关系数r=-0.487,P=0.007;T1WI双回波肝脏信号强度指数与肝脾的CT值之差也呈显著负相关关系,相关系数r=-0.474,P-0.007。T1WI双回波与CT值在反映脂肪肝的程度方面,其评估具有一致性。
2、T1WI双回波肝脏信号强度指数诊断脂肪肝的ROC曲线下面积(Az)为0.950±0.031。CT扫描肝脾CT值比值诊断脂肪肝的Az为0.938±0.056,肝脾CT差值的Az为0.940±0.053;三者相比差异无显著性(P值分别为0.85、0.87、0.44)。
3、在T1WI正相位图像,无脂肪肝背景组HCC病灶的CNR绝对值略低于脂肪肝组(-47±8 VS-48±14.1),差别无显著性(P=0.946);反相位两组病灶CNR值分别为-28.12±7.04、-9.67±11.41,虽然CNR绝对值存在差异,但差别仍无显著性意义(P=0.175)。
4、T1WI双回波图像中,正常肝脏背景组与脂肪肝组HCC病灶的CNR变化差值分别为-18.22±3.98、-38.40±8.86,脂肪肝组病灶CNR变化较对照组显著(P=0.023)。
结论:在HCC疑似或高危人群中,MR化学位移T1WI双回波图像对脂肪肝的评估与CT一致,均有很高的诊断效能;HCC伴有脂肪肝时,病灶在T1WI双回波图像的显示会发生显著变化。
第二部分CT三期增强与MRI多期动态增强扫描诊断肝细胞肝癌的对比分析
目的:比较多排螺旋CT三期增强、3-T MR多期动态增强扫描对HCC的诊断效能;对比CT单动脉期与MR双动脉期扫描对HCC病灶的显示能力。
材料与方法:2008年6月到2009年2月,共60例临床疑似或HCC高危患者纳入本研究,并完成CT及MR检查。39例确诊为HCC,共59个HCC灶,其中男性35例,女性4例,年龄35—74岁(平均56.1岁)。CT采用平扫加三期增强,MR采用LAVA技术双动脉期、双门脉期、双静脉期、2—3分钟延迟期,共7期动态增强扫描。通过对三位观测者的CT和MR观测数据行Alternative-free-responseROC(AFROC)曲线分析,并计算曲线下面积(Az),比较两种方法的诊断效能。另外单独比较CT动脉期和MR双动脉期对HCC病灶的显示能力。
结果:1、CT增强扫描的Az平均值0.812±0.0118,MR多期动态增强扫描的Az平均值0.9093±0.0072,差别均无显著性意义(P值分别为0.15、0.14、0.09)。在＜1cm的HCC病灶组,CT和MR增强扫描的平均敏感性为63.9%和80.5%,MR高于CT扫描(P=0.013)。在1—3cm组和＞3cm组,CT和MR增强扫描诊断的敏感性差别均无显著性(P＞0.05)。在所有病灶中,CT多期增强扫描的敏感性低于MR动态增强扫描(83.6%VS 88.7%),差异无显著性(P＞0.05),CT阳性预测值(PPV)也低于MR扫描(93.1%VS 96.3%),差异无显著性(P＞0.05)。
2、MR动脉早期对病灶检出敏感性和PPV分别为67.8%和93.6%,MR动脉中期与动脉双期扫描的敏感性和PPV均相同,分别为84.6%和87.9%;MR动脉早期对HCC病灶的总体检出敏感性低于动脉中期和双动脉期(P=0.034)。CT动脉期对病灶检出的敏感性和PPV分别为76.6%和92.9%,CT动脉期对病灶的检出敏感性低于MR双动脉期,但差异无显著性意义(P=0.073);CT动脉期的阳性预测值高于MR双期,差异无显著性意义(P=0.58)。
3、CT动脉期和MR双动脉期对＜1cm组HCC病灶的敏感性平均值分别为55.5%、75%,MR双动脉期的敏感性显著高于CT动脉期(P=0.036);在1—3cm组,CT动脉期与MR双动脉期的敏感性分别为71.2%、82.7%,但差异无显著性意义(P=0.24);在＞3cm组,CT动脉期与MR双动脉期的敏感性分别为95%、96.7%,差异无显著性意义(P=0.21)。
结论:对小于1cm的病灶,MR增强扫描的敏感性高于CT扫描;大于1cm的病灶,两者的诊断敏感性无显著差别。病灶体积越大,MR双动脉期、CT动脉期显示病灶的敏感性越高,但其敏感性和阳性预测值无显著差异。MR双动脉期扫描时,动脉早期扫描诊断价值有限。
第三部分CT及MR多期动态增强扫描对肝细胞肝癌介入后随诊的对比分析
目的:比较多排螺旋CT与MR多期动态增强扫描对肝细胞肝癌(HCC)经肝动脉化疗栓塞(TACE)后肿瘤局灶复发或残存的诊断价值。
材料与方法:18例结节型HCC患者共38个病灶,TACE介入后45天到11个月分别行多排螺旋CT增强扫描及MR多期增强扫描,检查平均间隔9天(1-21天)。两位影像诊断医生分别读片,评价肿瘤复发或残存。所有病灶经临床化验、血管造影、TACE后CT随诊等方法证实。通过计算两种诊断方法的ROC曲线下面积(Az),比较两者诊断的准确性。并评价CT及MR诊断的敏感性差异。
结果:所有38个病灶中,24个(63.2%)有肿瘤残存或复发。两位观测者的诊断评分具有较高的一致性(κ值为0.732,P＜0.05)。CT动态增强ROC曲线下面积平均为0.751,MR多期增强ROC曲线下面积平均为0.949,差异具有显著性(两位观测者的P值分别为0.037、0.050),表明MR多期增强扫描诊断的效能高于CT增强扫描。CT诊断HCC病灶复发或残存的敏感性和阳性预测值(PPV)平均分别为43.8%和100%;MR诊断的敏感性和PPV平均值分别为84.5%和93.3%;MR诊断敏感性显著高于CT扫描(两位观测者P值分别为0.006和0.005)。
结论:在评估肝细胞肝癌TACE治疗后肿瘤残存或复发方面,MR多期增强扫描优于CT增强扫描。
Part I
Hepatocelluar Carinoma with Nonalcoholic Fatty Liver Background:Quantitative Evaluation of MR Double-echo Chemical Shift T1 Weighted Images and Compared with CT Images
Purpose:CT and MR scan were performed in patients with hepatocellular carcinoma, the fatty liver background and HCCs were quantitatively evaluated by chemical shift double-echo T1 weighted imaging,and compared with CT scan.
Materials and Methods:Between June 2008 and February 2009,the suspected and risk patients with HCC were performed multiple-detector CT and 3-T MR scan.The patients with liver background abnormal were ruled out except for nonalcoholic fatty liver.A total 46 HCC patients were fit into our study(male 39,female 7,ranged 35-76 years old,mean age 50.53 years).The HCC cases were divided into two groups,the fatty liver(11 cases) and normal background of liver(35 cases).The images and clinical data were available in all patients.The ROC curve was used to compared the ability of quantitative evaluation for fat content in the liver at CT and dual-echo T1WI images.The different HCCs features of contrast noise rate(CNR) in fatty liver were also compared at MR images.
Result:
1.To evaluate the fat content in the liver,the signal intensity(SI) index of dual-echo T1WI showed a linear negative correlation with liver-to-spleen CT value ratio,the correlation was significant(r=-0.487,P=0.007).A significant linear negative correlation (r=-0.474,P=0.007) was also found between the SI index of dual-echo T1WI and liver-to-spleen CT value difference.
2.For the evaluation of fatty liver,the area under ROC(area index Az) value of dual-echo T1WI was 0.950±0.031,the Az value of liver-to-spleen CT ratio was 0.938± 0.056,the Az value of liver-to spleen CT value difference was 0.940±0.053.Compared between any two means,the differences were not significant(the P values were 0.85, 0.87,0.44,respectively).
3.Compared with the fatty liver group,the CNR of HCCs in control group was higher(-47±8 VS -48±14.1) at the in-phase MR images,but the difference was not significant(P=0.946).At the opposed images,the CNR values of HCCs were -28.12±7.04 and -9.67±11.41,respectively,the difference was not significant(P=0.175) too.
4.At the dual-echo T1WI,the mean CNR variation of HCCs in control group and study group was -18.22±3.98 and -38.40±8.86,respectively.The difference was significant(P=0.023).
Conclusion:The quantitative evaluation of fat content in the liver for the patients with HCC,the dual-echo T1WI appeared a consistent with CT.The intensity of HCCs at dual-echo T1WI appeared a significant change in the fatty liver background.
Purpose:Triple-phase enhancement CT and multiple-phase dynamic-enhancement MR scan were performed in patients with hepatocellular carcinoma(HCC).The diagnostic ability of the two methods was compared.The detectability of dual-arterial phase of MRI and single-artery phase of CT scan for HCCs was evaluated.
Materials and methods:Between June 2008 and February 2009,a total of 60 patients suspected or risk of HCC were performed CT and MR scan.59 HCCs were confirmed in 39 patients(male 35,female 4,ranged 35-74 years old,mean aged 56.1 years).CT was performed with routine CT scan and a triple-phase enhancement scan. MR imaging was performed with LAVA technique,the images included mask images, dual-artery phases,dual-portal phases,dual-venous phases and 2-3 minute delayed phase. Three observers evaluated the CT and MR imaging separately,and the results were compared with alternative-free-response ROC(AFROC) curve,the area under ROC(Az) was calculated to compare the diagnostic ability.In addition,the detectability of dual-artery phase of MR images was compared with the single-artery phase of CT images.
Result:
1.The Az value of CT for the diagnosis of HCC was 0.812±0.0118,the Az value of MR was 0.909±0.0072,the difference was not significant(P value of three observers was 0.15,0.14,0.09,respectively).In the group of less than 1cm in the diameter of HCCs,the sensitivity of CT and MR was 63.9%and 80.5%,the difference was not significant (P=0.013).In the groups of 1-3cm and larger than 3cm of HCCs,the sensitivity of CT and MR appeared no significant difference(P＞0.05).Of all HCCs,the sensitivity of CT was lower than MR(83.6%VS 88.7%),but the difference was not significant(P＞0.05). The positive predict value(PPV) of CT was also lower than MR(93.1 VS 96.3%),but the difference was not significant too(P＞0.05).
2.The mid-artery phase had the same sensitivity and PPV with dual-artery phase of MR of 84.6%and 87.95,respectively.The early-artery phase of MR appeared a significantly lower sensitivity of 67.8%(P=0.034),PPV of early-artery phase imaging was 93.6%.The artery phase of CT scan had a sensitivity and PPV of 76.6%and 92.9%, respectively.The sensitivity was lower than double-artery phase of MR imaging,and the PPV was higher,but the difference was not significant(p=0.58).
3.In the group of less than 1cm in diameter of HCCs,the sensitivity of CT single-artery phase images and MR dual-artery phase images was 55.5%and 75%, respectively,the later showed a higher sensitivity(P=0.036).In the groups of 1-3cm and＞3cm,the sensitivity of the two technique compared no significant difference(71.2% VS 82.7%,P=0.24.And 95%VS 96.7%,P=0.21).
Conclusion:The diagnostic ability of triple-phase enhancement CT and multiple-phase dynamic-enhancement MR scan for HCCs was similar.For the lesions less than 1cm in diameter,the dynamic-enhancement MR was superior to that of contrast-enhancement CT scan.While for the larger ones,the difference was not significant.For the detection of HCCs,the early-artery phase MR images did not provide additional benefit for dual-artery phase enhanced MRI detectability.
Purpose:To compare the detectability of MR Dynamic enhancement with that of Contrast-enhanced CT for the detection of local hepatocellular carcinoma(HCC) recurrence post-transcatheter arterial chemoembolization(TACE).
Materials and methods:Eighteen patients with 38 HCCs underwent MR and spiral CT scan with a mean interval of 9 days(range,1-21days) after 45 days to 11 months of TACE.The enhanced MRI examination was performed with a LAVA technology on a 3-T unit.Both MRI and CT scan included multiphase imaging.Two observers independently interpreted the CT and MR images blindly.The diagnostic ability of the two techniques was evaluated by comparing the area under the ROC curve(Az value).The sensitivity was also evaluated.
Results:Of all 38 HCCs,24(63.2%) lesions were confirmed local recurrence after TACE.The observers appeared a high consistent with the diagnosis(a kappa value of 0.732,P＜0.05).The Az value of contrast-enhancement MRI was higher than that of dynamic enhanced CT scan(0.949 VS 0.751,a P value was 0.037 and 0.050,respectively. The diagnostic ability of MR LAVA was higher than that of dynamic CT scan for the local HCCs recurrence.The sensitivity of contrast-enhancement MRI for the detection of recurrence was higher than CT scan(84.5%vs 43.8%,P＜0.05).
Conclusion:Contrast-enhancement MRI has a high diagnostic ability of detecting local recurrence of HCC post transcatheter arterial chemoenbolization comparing contrast-enhanced CT scan.
材料与方法:2008年6月至2009年2月,对临床疑似或HCC高危人群行多排螺旋CT及3-T MR扫描,排除脂肪肝以外的肝脏背景异常后,共46例HCC患者纳入本研究,其中男性39例,女性7例,年龄35-76岁(平均50.53岁)。本研究患者被分为两组:非酒精性脂肪肝组(11例)和肝脏背景无异常组(35例)。所有患者有完整的多排螺旋平扫图像、MR化学位移T1WI正反相位图像,以及完整的临床资料。对CT及MR诊断脂肪肝进行一致性检验,并采用AFROC曲线分析,对比CT及T1WI双回波图像定量评估脂肪肝背景的效能,并对比不同肝脏背景下HCC病灶的对比噪声比(CNR)变化特征。
结果:1、所有46例患者中,在评估脂肪肝程度方面,T1WI双回波肝脏信号强度指数的大小与CT扫描的肝、脾CT值之比呈显著负相关关系,相关系数r=-0.487,P=0.007;T1WI双回波肝脏信号强度指数与肝脾的CT值之差也呈显著负相关关系,相关系数r=-0.474,P-0.007。T1WI双回波与CT值在反映脂肪肝的程度方面,其评估具有一致性。
2、T1WI双回波肝脏信号强度指数诊断脂肪肝的ROC曲线下面积(Az)为0.950±0.031。CT扫描肝脾CT值比值诊断脂肪肝的Az为0.938±0.056,肝脾CT差值的Az为0.940±0.053;三者相比差异无显著性(P值分别为0.85、0.87、0.44)。
3、在T1WI正相位图像,无脂肪肝背景组HCC病灶的CNR绝对值略低于脂肪肝组(-47±8 VS-48±14.1),差别无显著性(P=0.946);反相位两组病灶CNR值分别为-28.12±7.04、-9.67±11.41,虽然CNR绝对值存在差异,但差别仍无显著性意义(P=0.175)。
4、T1WI双回波图像中,正常肝脏背景组与脂肪肝组HCC病灶的CNR变化差值分别为-18.22±3.98、-38.40±8.86,脂肪肝组病灶CNR变化较对照组显著(P=0.023)。
结论:在HCC疑似或高危人群中,MR化学位移T1WI双回波图像对脂肪肝的评估与CT一致,均有很高的诊断效能;HCC伴有脂肪肝时,病灶在T1WI双回波图像的显示会发生显著变化。
第二部分CT三期增强与MRI多期动态增强扫描诊断肝细胞肝癌的对比分析
目的:比较多排螺旋CT三期增强、3-T MR多期动态增强扫描对HCC的诊断效能;对比CT单动脉期与MR双动脉期扫描对HCC病灶的显示能力。
材料与方法:2008年6月到2009年2月,共60例临床疑似或HCC高危患者纳入本研究,并完成CT及MR检查。39例确诊为HCC,共59个HCC灶,其中男性35例,女性4例,年龄35—74岁(平均56.1岁)。CT采用平扫加三期增强,MR采用LAVA技术双动脉期、双门脉期、双静脉期、2—3分钟延迟期,共7期动态增强扫描。通过对三位观测者的CT和MR观测数据行Alternative-free-responseROC(AFROC)曲线分析,并计算曲线下面积(Az),比较两种方法的诊断效能。另外单独比较CT动脉期和MR双动脉期对HCC病灶的显示能力。
结果:1、CT增强扫描的Az平均值0.812±0.0118,MR多期动态增强扫描的Az平均值0.9093±0.0072,差别均无显著性意义(P值分别为0.15、0.14、0.09)。在＜1cm的HCC病灶组,CT和MR增强扫描的平均敏感性为63.9%和80.5%,MR高于CT扫描(P=0.013)。在1—3cm组和＞3cm组,CT和MR增强扫描诊断的敏感性差别均无显著性(P＞0.05)。在所有病灶中,CT多期增强扫描的敏感性低于MR动态增强扫描(83.6%VS 88.7%),差异无显著性(P＞0.05),CT阳性预测值(PPV)也低于MR扫描(93.1%VS 96.3%),差异无显著性(P＞0.05)。
2、MR动脉早期对病灶检出敏感性和PPV分别为67.8%和93.6%,MR动脉中期与动脉双期扫描的敏感性和PPV均相同,分别为84.6%和87.9%;MR动脉早期对HCC病灶的总体检出敏感性低于动脉中期和双动脉期(P=0.034)。CT动脉期对病灶检出的敏感性和PPV分别为76.6%和92.9%,CT动脉期对病灶的检出敏感性低于MR双动脉期,但差异无显著性意义(P=0.073);CT动脉期的阳性预测值高于MR双期,差异无显著性意义(P=0.58)。
3、CT动脉期和MR双动脉期对＜1cm组HCC病灶的敏感性平均值分别为55.5%、75%,MR双动脉期的敏感性显著高于CT动脉期(P=0.036);在1—3cm组,CT动脉期与MR双动脉期的敏感性分别为71.2%、82.7%,但差异无显著性意义(P=0.24);在＞3cm组,CT动脉期与MR双动脉期的敏感性分别为95%、96.7%,差异无显著性意义(P=0.21)。
结论:对小于1cm的病灶,MR增强扫描的敏感性高于CT扫描;大于1cm的病灶,两者的诊断敏感性无显著差别。病灶体积越大,MR双动脉期、CT动脉期显示病灶的敏感性越高,但其敏感性和阳性预测值无显著差异。MR双动脉期扫描时,动脉早期扫描诊断价值有限。
第三部分CT及MR多期动态增强扫描对肝细胞肝癌介入后随诊的对比分析
目的:比较多排螺旋CT与MR多期动态增强扫描对肝细胞肝癌(HCC)经肝动脉化疗栓塞(TACE)后肿瘤局灶复发或残存的诊断价值。
材料与方法:18例结节型HCC患者共38个病灶,TACE介入后45天到11个月分别行多排螺旋CT增强扫描及MR多期增强扫描,检查平均间隔9天(1-21天)。两位影像诊断医生分别读片,评价肿瘤复发或残存。所有病灶经临床化验、血管造影、TACE后CT随诊等方法证实。通过计算两种诊断方法的ROC曲线下面积(Az),比较两者诊断的准确性。并评价CT及MR诊断的敏感性差异。
结果:所有38个病灶中,24个(63.2%)有肿瘤残存或复发。两位观测者的诊断评分具有较高的一致性(κ值为0.732,P＜0.05)。CT动态增强ROC曲线下面积平均为0.751,MR多期增强ROC曲线下面积平均为0.949,差异具有显著性(两位观测者的P值分别为0.037、0.050),表明MR多期增强扫描诊断的效能高于CT增强扫描。CT诊断HCC病灶复发或残存的敏感性和阳性预测值(PPV)平均分别为43.8%和100%;MR诊断的敏感性和PPV平均值分别为84.5%和93.3%;MR诊断敏感性显著高于CT扫描(两位观测者P值分别为0.006和0.005)。
结论:在评估肝细胞肝癌TACE治疗后肿瘤残存或复发方面,MR多期增强扫描优于CT增强扫描。
Part I
Hepatocelluar Carinoma with Nonalcoholic Fatty Liver Background:Quantitative Evaluation of MR Double-echo Chemical Shift T1 Weighted Images and Compared with CT Images
Purpose:CT and MR scan were performed in patients with hepatocellular carcinoma, the fatty liver background and HCCs were quantitatively evaluated by chemical shift double-echo T1 weighted imaging,and compared with CT scan.
Materials and Methods:Between June 2008 and February 2009,the suspected and risk patients with HCC were performed multiple-detector CT and 3-T MR scan.The patients with liver background abnormal were ruled out except for nonalcoholic fatty liver.A total 46 HCC patients were fit into our study(male 39,female 7,ranged 35-76 years old,mean age 50.53 years).The HCC cases were divided into two groups,the fatty liver(11 cases) and normal background of liver(35 cases).The images and clinical data were available in all patients.The ROC curve was used to compared the ability of quantitative evaluation for fat content in the liver at CT and dual-echo T1WI images.The different HCCs features of contrast noise rate(CNR) in fatty liver were also compared at MR images.
Result:
1.To evaluate the fat content in the liver,the signal intensity(SI) index of dual-echo T1WI showed a linear negative correlation with liver-to-spleen CT value ratio,the correlation was significant(r=-0.487,P=0.007).A significant linear negative correlation (r=-0.474,P=0.007) was also found between the SI index of dual-echo T1WI and liver-to-spleen CT value difference.
2.For the evaluation of fatty liver,the area under ROC(area index Az) value of dual-echo T1WI was 0.950±0.031,the Az value of liver-to-spleen CT ratio was 0.938± 0.056,the Az value of liver-to spleen CT value difference was 0.940±0.053.Compared between any two means,the differences were not significant(the P values were 0.85, 0.87,0.44,respectively).
3.Compared with the fatty liver group,the CNR of HCCs in control group was higher(-47±8 VS -48±14.1) at the in-phase MR images,but the difference was not significant(P=0.946).At the opposed images,the CNR values of HCCs were -28.12±7.04 and -9.67±11.41,respectively,the difference was not significant(P=0.175) too.
4.At the dual-echo T1WI,the mean CNR variation of HCCs in control group and study group was -18.22±3.98 and -38.40±8.86,respectively.The difference was significant(P=0.023).
Conclusion:The quantitative evaluation of fat content in the liver for the patients with HCC,the dual-echo T1WI appeared a consistent with CT.The intensity of HCCs at dual-echo T1WI appeared a significant change in the fatty liver background.
Purpose:Triple-phase enhancement CT and multiple-phase dynamic-enhancement MR scan were performed in patients with hepatocellular carcinoma(HCC).The diagnostic ability of the two methods was compared.The detectability of dual-arterial phase of MRI and single-artery phase of CT scan for HCCs was evaluated.
Materials and methods:Between June 2008 and February 2009,a total of 60 patients suspected or risk of HCC were performed CT and MR scan.59 HCCs were confirmed in 39 patients(male 35,female 4,ranged 35-74 years old,mean aged 56.1 years).CT was performed with routine CT scan and a triple-phase enhancement scan. MR imaging was performed with LAVA technique,the images included mask images, dual-artery phases,dual-portal phases,dual-venous phases and 2-3 minute delayed phase. Three observers evaluated the CT and MR imaging separately,and the results were compared with alternative-free-response ROC(AFROC) curve,the area under ROC(Az) was calculated to compare the diagnostic ability.In addition,the detectability of dual-artery phase of MR images was compared with the single-artery phase of CT images.
Result:
1.The Az value of CT for the diagnosis of HCC was 0.812±0.0118,the Az value of MR was 0.909±0.0072,the difference was not significant(P value of three observers was 0.15,0.14,0.09,respectively).In the group of less than 1cm in the diameter of HCCs,the sensitivity of CT and MR was 63.9%and 80.5%,the difference was not significant (P=0.013).In the groups of 1-3cm and larger than 3cm of HCCs,the sensitivity of CT and MR appeared no significant difference(P＞0.05).Of all HCCs,the sensitivity of CT was lower than MR(83.6%VS 88.7%),but the difference was not significant(P＞0.05). The positive predict value(PPV) of CT was also lower than MR(93.1 VS 96.3%),but the difference was not significant too(P＞0.05).
2.The mid-artery phase had the same sensitivity and PPV with dual-artery phase of MR of 84.6%and 87.95,respectively.The early-artery phase of MR appeared a significantly lower sensitivity of 67.8%(P=0.034),PPV of early-artery phase imaging was 93.6%.The artery phase of CT scan had a sensitivity and PPV of 76.6%and 92.9%, respectively.The sensitivity was lower than double-artery phase of MR imaging,and the PPV was higher,but the difference was not significant(p=0.58).
3.In the group of less than 1cm in diameter of HCCs,the sensitivity of CT single-artery phase images and MR dual-artery phase images was 55.5%and 75%, respectively,the later showed a higher sensitivity(P=0.036).In the groups of 1-3cm and＞3cm,the sensitivity of the two technique compared no significant difference(71.2% VS 82.7%,P=0.24.And 95%VS 96.7%,P=0.21).
Conclusion:The diagnostic ability of triple-phase enhancement CT and multiple-phase dynamic-enhancement MR scan for HCCs was similar.For the lesions less than 1cm in diameter,the dynamic-enhancement MR was superior to that of contrast-enhancement CT scan.While for the larger ones,the difference was not significant.For the detection of HCCs,the early-artery phase MR images did not provide additional benefit for dual-artery phase enhanced MRI detectability.
Purpose:To compare the detectability of MR Dynamic enhancement with that of Contrast-enhanced CT for the detection of local hepatocellular carcinoma(HCC) recurrence post-transcatheter arterial chemoembolization(TACE).
Materials and methods:Eighteen patients with 38 HCCs underwent MR and spiral CT scan with a mean interval of 9 days(range,1-21days) after 45 days to 11 months of TACE.The enhanced MRI examination was performed with a LAVA technology on a 3-T unit.Both MRI and CT scan included multiphase imaging.Two observers independently interpreted the CT and MR images blindly.The diagnostic ability of the two techniques was evaluated by comparing the area under the ROC curve(Az value).The sensitivity was also evaluated.
Results:Of all 38 HCCs,24(63.2%) lesions were confirmed local recurrence after TACE.The observers appeared a high consistent with the diagnosis(a kappa value of 0.732,P＜0.05).The Az value of contrast-enhancement MRI was higher than that of dynamic enhanced CT scan(0.949 VS 0.751,a P value was 0.037 and 0.050,respectively. The diagnostic ability of MR LAVA was higher than that of dynamic CT scan for the local HCCs recurrence.The sensitivity of contrast-enhancement MRI for the detection of recurrence was higher than CT scan(84.5%vs 43.8%,P＜0.05).
Conclusion:Contrast-enhancement MRI has a high diagnostic ability of detecting local recurrence of HCC post transcatheter arterial chemoenbolization comparing contrast-enhanced CT scan.
引文
1.Hussain K,El-Serag HB.Epidemiology,screening,diagnosis and treatment of hepatocellular carcinoma[J].Minerva Gastroenterol Dietol 2009;55:123-138
2.Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis[J].World J Gastroenterol 2008;14:4300-4308
3.Angulo P.Nonalcoholic fatty liver disease[J].N Engl J Med 2002;346:1221-1231
4.Hashimoto E,Yatsuji S,Tobari M,et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].J Gastroenterol 2009;44 Suppl 19:89-95
5.Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States[J].Hepatology 2002;36:1349-1354
6.Guzman G,Brunt EM,Petrovic LM,Chejfec G,Layden TJ,Cotler SJ.Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?[J]Arch Pathol Lab Med 2008;132:1761-1766
7.Bullock RE,Zaitoun AM,Aithal GP,Ryder SD,Beckingham IJ,Lobo DN.Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma[J].J Hepatol 2004;41:685-686
8.Mori S,Yamasaki T,Sakaida I,et al.Hepatocellular carcinoma with nonalcoholic steatohepatitis[J].J Gastroenterol 2004;39:391-396
9.Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology[J]2002;123:1705-1725
10.Valls C,Iannacconne R,Alba E,et al.Fat in the liver:diagnosis and characterization[J].Eur Radiol 2006;16:2292-2308
11.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2006年2月修订)[J].现代消化与介入诊疗 2007;12:3
12.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001;9:324-325
13.Brancatelli G,Federle MP,Grazioli L,Carr BI.Hepatocellular carcinoma in noncirrhotic liver:CT,clinical,and pathologic findings in 39 U.S.residents[J].Radiology 2002;222:89-94
14.Iannaccone R,Piacentini F,Murakami T,et al.Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease:helical CT and MR imaging findings with clinical-pathologic comparison.[J]Radiology 2007;243:422-430
15.贺文,马大庆,冯捷,胡志海,钱林学,赵继学.CT定量诊断脂肪肝的临床研究[J].中华放射学杂志2001;35:829-833
16.Limanond P,Raman SS,Lassman C,et al.Macrovesicular hepatic steatosis in living related liver donors:correlation between CT and histologic findings[J].Radiology 2004;230:276-280
17.Namimoto T,Yamashita Y,Mitsuzaki K,et al.Adrenal masses:quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas[J].Radiology 2001;218:642-646
18.Tsushima Y,Dean PB.Characterization of adrenal masses with chemical shift MR imaging:how to select echo times[J].Radiology 1995;195:285-286
19.Yoshikawa J,Matsui O,Takashima T,et al.Fatty metamorphosis in hepatocellular carcinoma:radiologic features in 10 cases[J].AJR Am J Roentgenol 1988;151:717-720
20.Yu JS,Chung JJ,Kim JH,Kim KW.Fat-containing nodules in the cirrhotic liver:chemical shift MRI features and clinical implications[J].AJR Am J Roentgenol 2007;188:1009-1016
1.Robinson P.Hepatocellular carcinoma:development and early detection[J].Cancer Imaging 2008;8 Suppl A:S128-131
2.Rode A,Bancel B,Douek P,et al.Small nodule detection in cirrhotic livers:evaluation with US,spiral CT,and MRI and correlation with pathologic examination of explanted liver[J].J Comput Assist Tomogr 2001;25:327-336
3.Kim YK,Kim CS,Chung GH,et al.Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma[J].AJR Am J Roentgenol 2006;186:149-157
4.Sahani DV,Kalva SP.Imaging the liver[J].Oncologist 2004;9:385-397
5.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001;9:324-325
6.周纯武,赵心明,孙伟,刘尚梅.小肝癌的CT表现——31例与病理对照分析[J].中国医学影像技术2001;17:1175-1177
7.Secil M,Obuz F,Altay C,et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma[J].Diagn Interv Radiol 2008;14:200-204
8.Hecht EM,Holland AE,Israel GM,et al.Hepatocellular carcinoma in the cirrhotic liver:gadolinium-enhanced 3D Tl-weighted MR imaging as a stand-alone sequence for diagnosis[J].Radiology 2006;239:438-447
9.Kim SJ,Kim SH,Lee J,et al.Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma[J].In:J Comput Assist Tomogr,2008:379-385
10.Willatt JM,Hussain HK,Adusumilli S,Marrero JA.MR Imaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology 2008;247:311-330
11.Yu JS,Chung JJ,Kim JH,Kim KW.Fat-containing nodules in the cirrhotic liver:chemical shift MRI features and clinical implications[J].AJR Am J Roentgenol 2007;188:1009-1016
12.Murakami T,Kim T,Takamura M,et al.Hypervascular hepatocellular carcinoma:detection with double arterial phase multi-detector row helical CT[J].Radiology 2001;218:763-767
13.Ichikawa T,Kitamura T,Nakajima H,et al.Hypervascular hepatocellular carcinoma:can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver?[J]AJR Am J Roentgeno12002;179:751-758
14.Noguchi Y,Murakami T,Kim T,et al.Detection of hepatocellular carcinoma:comparison of dynamic MR imaging with dynamic double arterial phase helical CT[J].AJR Am J Roentgenol 2003;180:455-460
15.Yanaga Y,Awai K,Nakaura T,et al.Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT[J].AJR Am J Roentgenol 2008;190:1003-1009
16.Furuta A,Ito K,Fujita T,Koike S,Shimizu A,Matsunaga N.Hepatic enhancement in multiphasic contrast-enhanced MDCT:comparison of high-and low-iodine-concentration contrast medium in same patients with chronic liver disease[J].AJR Am J Roentgenol 2004;183:157-162
17.Schima W,Hammerstingl R,Catalano C,et al.Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma:effect of contrast material flow rate[J].AJR Am J Roentgenol 2006;186:1571-1579
18.Holland AE,Hecht EM,Hahn WY,et al.Importance of small (＜or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver:evaluation and comparison with whole explanted liver[J],Radiology 2005;237:938-944
19.Denecke T,Grieser C,Froling V,et al.Multislice computed tomography using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation[J].Transpl Int 2009;22:395-402
20.Li CS,Chen RC,Tu HY,et al.Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography[J].Br J Radiol 2006;79:659-665
21.Roncalli M,Borzio M,Di Tommaso L.Hepatocellular dysplastic nodules[J].Ann ltd Chir 2008;79:81-89
22.Jang HJ,Kim TK,Burns PN,Wilson SR.Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US:comparison with histologic differentiation[J].Radiology 2007;244:898-906
23.Tandon P,Garcia-Tsao G.Prognostic indicators in hepatocellular carcinoma:a systematic review of 72 studies[J].Liver Int 2009;29:502-510
1.Kubota K,Hisa N,Nishikawa T,et al.Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization:comparison of Lipiodol-CT,power Doppler sonography,and dynamic MRI[J].Abdom Imaging 2001;26:184-190
2.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology 2005;42:1208-1236
3.Takayasu K,Arii S,Ikai I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology 2006;131:461-469
4.Palma LD.Diagnostic imaging and interventional therapy of hepatocellular carcinoma[J].Br J Radiol 1998;71:808-818
5.Guan YS,Sun L,Zhou XP,Li X,Zheng XH.Hepatocellular carcinoma treated with interventional procedures:CT and MRI follow-up[J].World J Gastroenterol 2004;10:3543-3548
6.Ebied OM,Federle MP,Carr Bl,et al.Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma[J].Cancer 2003;97:1042-1050
7.De Santis M,Alborino S,Tartoni PL,Torricelli P,Casolo A,Romagnoli R.Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization[J].Eur Radiol 1997;7:10-16
8.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001:9:324-325
9.Zangos S,Eichler K,Balzer JO,et al.Large-sized hepatocellular carcinoma(HCC):a neoadjuvant treatment protocol with repetitive transarterial chemoembolization(TACE)before percutaneous MR-guided laser-induced thermotherapy(LITT)[J].Eur Radiol 2007;17:553-563
10.Pleguezuelo M,Marelli L,Misseri M,et al.TACE versus TAE as therapy for hepatocellular carcinoma[J].Expert Rev Anticancer Ther 2008;8:1623-1641
11.Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology 2003;37:429-442
12.Osuga K,Hori S,Hiraishi K,et al.Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres[J].Cardiovasc Intervent Radiol 2008;31:1108-1116
13.邹子扬,赵春梅,李双成,吴飞.海藻酸钠微球血管栓塞剂栓塞治疗原发性肝癌临床研究[J].临床荟萃2006;21:869-872
14.Saccheri S,Lovaria A,Sangiovanni A,et al.Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas[J].J Vasc Interv Radiol 2002;13:995-999
15.Goshima S,Kanematsu M,Matsuo M,et al.Early-enhancing nonneoplastic lesions on gadolinium-enhanced magnetic resonance imaging of the liver following partial hepatectomy[J].J Magn Reson Imaging 2004;20:66-74
16.Ito K,Honjo K,Fujita T,et al.Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma:MRI and pathology[J].J Comput Assist Tomogr 1995;19:198-203
17.张雄彪,王耿,唐玉德,刘树学.Propeller LAVA技术对原发性肝癌MRI的诊断价值[J]实用医技杂志2007;14:1520-1524
18.Chakraborty DP,Winter LH.Free-response methodology:alternate analysis and a new observer-performance experiment[J].Radiology 1990;174:873-881
1.Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis[J].World J Gastroenterol 2008;14:4300-4308
2.Coleman WB.Mechanisms of human hepatocarcinogenesis[J].Curr Mol Med 2003;3:573-588
3.Efremidis SC,Hytiroglou P.The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation[J].Eur Radiol 2002;12:753-764
4.Kudo M.Multistep human hepatocarcinogenesis:correlation of imaging with pathology[J].J Gastroenterol 2009;44 Suppl 19:112-118
5.Krinsky GA,Lee VS.MR imaging of cirrhotic nodules[J].Abdom Imaging 2000;25:471-482
6.Ito K,Mitchell DG.Imaging diagnosis of cirrhosis and chronic hepatitis[J].Intervirology 2004;47:134-143
7.Shah TU,Semelka RC,Pamuklar E,et al.The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI[J].Am J Gastroenterol 2006;101:533-540
8.Terminology of nodular hepatocellular lesions.International Working Party[J].Hepatology 1995;22:983-993
9.Baron RL,Peterson MS.From the RSNA refresher courses:screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging:opportunities and pitfalls[J].Radiographics 2001;21 Spec No:S117-132
10.Lim JH,Kim EY,Lee WJ,et al.Regenerative nodules in liver cirrhosis:findings at CT during arterial portography and CT hepatic arteriography with histopathologic correlation[J].Radiology 1999;210:451-458
11.Freeny PC,Grossholz M,Kaakaji K,Schmiedl UP.Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients:radiologic-histopathologic correlation of explanted livers[J].Abdom Imaging 2003;28:333-346
12.Krinsky GA,Lee VS,Theise ND,et al.Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis:prospective diagnosis with MR imaging and explanation correlation[J].Radiology 2001;219:445-454
13.Theise ND,Schwartz M,Miller C,Thung SN.Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis[J].Hepatology 1992;16:949-955
14.Hytiroglou P,Theise ND.Differential diagnosis of hepatocellular nodular lesions[J].Semin Diagn Pathol 1998;15:285-299
15.Theise ND,Fiel IM,Hytiroglou P,et al.Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein[J].Liver 1995;15:30-34
16.Lim JH,Choi BI.Dysplastic nodules in liver cirrhosis:imaging[J].Abdom Imaging 2002;27:117-128
17.Park YN,Yang CP,Fernandez GJ,Cubukcu O,Thung SN,Theise ND.Neoangiogenesis and sinusoidal“capillarization”in dysplastic nodules of the liver[J].Am J Surg Pathol 1998;22:656-662
18.Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma[J].Lancet 2003;362:1907-1917
19.Taouli B,Goh JS,Lu Y,et al.Growth rate of hepatocellular carcinoma:evaluation with serial computed tomography or magnetic resonance imaging[J].J Comput Assist Tomogr 2005;29:425-429
20.Ikai I,Arii S,Kojiro M,et al.Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J].Cancer 2004;101:796-802
21.Arii S,Yamaoka Y,Futagawa S,et al.Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan.The Liver Cancer Study Group of Japan[J].Hepatology 2000;32:1224-1229
22.Willatt JM,Hussain HK,Adusumilli S,Marrero JA.MR Imaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology 2008;247:311-330
23.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology 2005;42:1208-1236
24.Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma[J].J Cancer Res Clin Oncol 2004;130:417-422
25.Lencioni R,Cioni D,Della Pina C,Crocetti L,Bartolozzi C.Imaging diagnosis[J].Semin Liver Dis 2005;25:162-170
26.Colli A,Fraquelli M,Casazza G,et al.Accuracy of ultrasonography,spiral CT,magnetic resonance,and alpha-fetoprotein in diagnosing hepatocellular carcinoma:a systematic review[J].Am J Gastroenterol 2006;101:513-523
27.Koito K,Namieno T,Morita K.Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography[J].AJR Am J Roentgenol 1998;170:157-161
28.D'Onofrio M,Faccioli N,Zamboni G,et al.Focal liver lesions in cirrhosis:value of contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels[J].Radiol Med 2008;113:978-991
29.D'Onofrio M,Rozzanigo U,Caffarri S,Zogno A,Procacci C.Contrast-enhanced US of hepatocellular carcinoma[J].Radiol Med 2004;107:293-303
30.Theise ND.Macroregenerative(dysplastic) nodules and hepatocarcinogenesis:theoretical and clinical considerations[J].Semin Liver Dis 1995;15:360-371
31.周纯武,赵心明,孙伟,刘尚梅.小肝癌的CT表现——31例与病理对照分析[J].中国医学影像技术2001;17:1175-1177
32.Noguchi Y,Murakami T,Kim T,et al.Detection of hepatocellular carcinoma:comparison of dynamic MR imaging with dynamic double arterial phase helical CT[J].AJR Am J Roentgenol 2003;180:455-460
33.韩新巍,邢古生,李永东.小肝癌的SCTAP及SCTA表现与血管造影的相关性研究[J].实用医学影像杂志2003;4:4
34.Yamashita Y,Mitsuzaki K,Yi T,et al.Small hepatocellular carcinoma in patients with chronic liver damage:prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver[J].Radiology 1996;200:79-84
35.Oi H,Murakami T,Kim T,Matsushita M,Kishimoto H,Nakamura H.Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma[J].AJR Am J Roentgenol 1996;166:369-374
36.Earls JP,Rofsky NM,DeCorato DR,Krinsky GA,Weinreb JC.Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging:optimization with a test examination and a power injector[J].Radiology 1997;202:268-273
37.Murakami T,Kuroda C,Marukawa T,et al.Regenerating nodules in hepatic cirrhosis:MR findings with pathologic correlation[J].AJR Am J Roentgenol 1990;155:1227-1231
38.Krinsky GA,Israel G.Nondysplastic nodules that are hyperintense on Tl-weighted gradient-echo MR imaging:frequency in cirrhotic patients undergoing transplantation[J].AJR Am J Roentgenol 2003;180:1023-1027
39.Mathieu D,Paret M,Mahfouz AE,et al.Hyperintense benign liver lesions on spin-echo Tl-weighted MR images:pathologic correlations[J].Abdom Imaging 1997;22:410-417
40.Vilgrain V,Lewin M,Vons C,et al.Hepatic nodules in Budd-Chiari syndrome:imaging features[J].Radiology 1999;210:443-450
41.Zhang J,Krinsky GA.Iron-containing nodules of cirrhosis[J].NMR Biomed2004;17:459-464
42.Ito K,Mitchell DG,Gabata T,et al.Hepatocellular carcinoma:association with increased iron deposition in the cirrhotic liver at MR imaging[J].Radiology 1999;212:235-240
43.Earls JP,Theise ND,Weinreb JC,et al.Dysplastic nodules and hepatocellular carcinoma:thin-section MR imaging of explanted cirrhotic livers with pathologic correlation[J].Radiology 1996;201:207-214
44.Krinsky GA,Lee VS,Nguyen MT,et al.Siderotic nodules in the cirrhotic liver at MR imaging with explant correlation:no increased frequency of dysplastic nodules and hepatocellular carcinoma[J].Radiology 2001;218:47-53
45.Sadek AG,Mitchell DG,Siegelman ES,Outwater EK,Matteucci T,Hann HW.Early hepatocellular carcinoma that develops within macroregenerative nodules:growth rate depicted at serial MR imaging[J].Radiology 1995;195:753-756
46.Muramatsu Y,Nawano S,Takayasu K,et al.Early hepatocellular carcinoma:MR imaging[J].Radiology 1991;181:209-213
47.Kim T,Baron RL,Nalesnik MA.Infarcted regenerative nodules in cirrhosis:CT and MR imaging findings with pathologic correlation[J].A JR Am J Roentgenol 2000;175:1121-1125
48.Seki S,Sakaguchi H,Kitada T,et al.Outcomes of dysplastic nodules in human cirrhotic liver:a clinicopathological study[J].Clin Cancer Res 2000;6:3469-3473
49.Hayashi M,Matsui O,Ueda K,et al.Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis:evaluation by CT during intraarterial injection of contrast medium[J].AJRAm J Roentgenol 1999;172:969-976
50.Goshima S,Kanematsu M,Matsuo M,et al.Nodule-in-nodule appearance of hepatocellular carcinomas:comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging[J].JMagn Reson Imaging 2004;20:250-255
51.Kim SJ,Kim SH,Lee J,et al.Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma[J].In:JComput Assist Tomogr,2008:379-385
52.Kelekis NL,Semelka RC,Woosley JT.Malignant lesions of the liver with high signal intensity on Tl-weighted MR images[J].J Magn Reson Imaging 1996;6:291-294
53.Ebara M,Fukuda H,Kojima Y,et al.Small hepatocellular carcinoma:relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchymal].Radiology 1999;210:81-88
54.Hussain HK,Syed I,Nghiem HV,et al.T2-weighted MR imaging in the assessment of cirrhotic liver[J].Radiology 2004;230:637-644
55.Hecht EM,Holland AE,Israel GM,et al.Hepatocellular carcinoma in the cirrhotic liver:gadolinium-enhanced 3D Tl-weighted MR imaging as a stand-alone sequence for diagnosis[J].Radiology 2006;239:438-447
56.Matsui O,Kadoya M,Kameyama T,et al.Benign and malignant nodules in cirrhotic livers:distinction based on blood supply[J].Radiology 1991;178:493-497
57.Matsui O.Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection[J].Intervirology 2004;47:271-276
58.Baron RL,Oliver JH,3rd,Dodd GD,3rd,Nalesnik M,Holbert BL,Carr B.Hepatocellular carcinoma:evaluation with biphasic,contrast-enhanced,helical CT[J].Radiology 1996;199:505-511
59.Ito K,Fujita T,Shimizu A,et al.Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis:differentiating between hypervascular hepatocellular carcinomas and pseudolesions[J].AJR Am J Roentgenol 2004;183:699-705
60.Ito K.Hepatocellular carcinoma:conventional MRI findings including gadolinium-enhanced dynamic imaging[J].Eur J Radiol 2006;58:186-199
61.Marrero JA,Hussain HK,Nghiem HV,Umar R,Fontana RJ,Lok AS.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass[J].Liver Transpl 2005;11:281-289
62.Bolondi L,Gaiani S,Celli N,et al.Characterization of small nodules in cirrhosis by assessment of vascularity:the problem of hypovascular hepatocellular carcinoma[J].Hepatology 2005;42:27-34
63.Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis[J].J Hepatol 2004;40:736-741
64.Takayasu K,Arii S,Ikai I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology 2006;131:461-469
65.Koike Y,Nakagawa K,Shiratori Y,et al.Factors affecting the prognosis of patients with hepatocellular carcinoma invading the portal vein~a retrospective analysis using 952 consecutive HCC patients[J].Hepatogastroenterology 2003;50:2035-2039
66.Aslam Sohaib SA,Teh J,Nargund VH,Lumley JS,Hendry WF,Reznek RH.Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging[J].J Urol 2002;167:1271-1275
67.Park JH,Koh KC,Choi MS,et al.Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma[J].Am J Surg 2006;192:29-33
68.Kim BW,Kim YB,Wang HJ,Kim MW.Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma[J].World J Gastroenterol 2006;12:99-104
69.Matsui O,Kadoya M,Yoshikawa J,et al.Aberrant gastric venous drainage in cirrhotic livers:imaging findings in focal areas of liver parenchymal].Radiology 1995;197:345-349
70.Itai Y,Matsui O.Blood flow and liver imaging[J].Radiology 1997;202:306-314
71.Holland AE,Hecht EM,Hahn WY,et al.Importance of small (＜or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver:evaluation and comparison with whole explanted liver[J].Radiology 2005;237:938-944
72.Peterson MS,Baron RL,Murakami T.Hepatic malignancies:usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging[J].Radiology 1996;201:337-345
73.Kelekis NL,Semelka RC,Worawattanakul S,et al.Hepatocellular carcinoma in North America:a multiinstitutional study of appearance on Tl-weighted,T2-weighted,and serial gadolinium-enhanced gradient-echo images[J].AJR Am J Roentgenol 1998;170:1005-1013
74.Brancatelli G,Baron RL,Peterson MS,Marsh W.Helical CT screening for hepatocellular carcinoma in patients with cirrhosis:frequency and causes of false-positive interpretation[J].AJR Am J Roentgenol 2003;180:1007-1014
75.Shimizu A,Ito K,Koike S,Fujita T,Shimizu K,Matsunaga N.Cirrhosis or chronic hepatitis:evaluation of small ( 76.Taouli B,Losada M,Holland A,Krinsky G.Magnetic resonance imaging of hepatocellular carcinoma[J].Gastroenterology 2004;127:S144-152
77.Stigliano R,Burroughs AK.Should we biopsy each liver mass suspicious for HCC before liver transplantation?~no,please don't[J].J Hepatol 2005;43:563-568
78.Marsh JW,Dvorchik I.Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?--yes[J].J Hepatol 2005;43:558-562
79.Chang S,Kim SH,Lim HK,Lee WJ,Choi D,Lim JH.Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma:evaluation of doubling time,frequency,and features on CT[J].AJR Am J Roentgenol 2005;185:400-405
80.Marrero JA,Lok AS.Newer markers for hepatocellular carcinoma[J].Gastroenterology 2004;127:S113-119
2.Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis[J].World J Gastroenterol 2008;14:4300-4308
3.Angulo P.Nonalcoholic fatty liver disease[J].N Engl J Med 2002;346:1221-1231
4.Hashimoto E,Yatsuji S,Tobari M,et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].J Gastroenterol 2009;44 Suppl 19:89-95
5.Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States[J].Hepatology 2002;36:1349-1354
6.Guzman G,Brunt EM,Petrovic LM,Chejfec G,Layden TJ,Cotler SJ.Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?[J]Arch Pathol Lab Med 2008;132:1761-1766
7.Bullock RE,Zaitoun AM,Aithal GP,Ryder SD,Beckingham IJ,Lobo DN.Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma[J].J Hepatol 2004;41:685-686
8.Mori S,Yamasaki T,Sakaida I,et al.Hepatocellular carcinoma with nonalcoholic steatohepatitis[J].J Gastroenterol 2004;39:391-396
9.Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology[J]2002;123:1705-1725
10.Valls C,Iannacconne R,Alba E,et al.Fat in the liver:diagnosis and characterization[J].Eur Radiol 2006;16:2292-2308
11.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2006年2月修订)[J].现代消化与介入诊疗 2007;12:3
12.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001;9:324-325
13.Brancatelli G,Federle MP,Grazioli L,Carr BI.Hepatocellular carcinoma in noncirrhotic liver:CT,clinical,and pathologic findings in 39 U.S.residents[J].Radiology 2002;222:89-94
14.Iannaccone R,Piacentini F,Murakami T,et al.Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease:helical CT and MR imaging findings with clinical-pathologic comparison.[J]Radiology 2007;243:422-430
15.贺文,马大庆,冯捷,胡志海,钱林学,赵继学.CT定量诊断脂肪肝的临床研究[J].中华放射学杂志2001;35:829-833
16.Limanond P,Raman SS,Lassman C,et al.Macrovesicular hepatic steatosis in living related liver donors:correlation between CT and histologic findings[J].Radiology 2004;230:276-280
17.Namimoto T,Yamashita Y,Mitsuzaki K,et al.Adrenal masses:quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas[J].Radiology 2001;218:642-646
18.Tsushima Y,Dean PB.Characterization of adrenal masses with chemical shift MR imaging:how to select echo times[J].Radiology 1995;195:285-286
19.Yoshikawa J,Matsui O,Takashima T,et al.Fatty metamorphosis in hepatocellular carcinoma:radiologic features in 10 cases[J].AJR Am J Roentgenol 1988;151:717-720
20.Yu JS,Chung JJ,Kim JH,Kim KW.Fat-containing nodules in the cirrhotic liver:chemical shift MRI features and clinical implications[J].AJR Am J Roentgenol 2007;188:1009-1016
1.Robinson P.Hepatocellular carcinoma:development and early detection[J].Cancer Imaging 2008;8 Suppl A:S128-131
2.Rode A,Bancel B,Douek P,et al.Small nodule detection in cirrhotic livers:evaluation with US,spiral CT,and MRI and correlation with pathologic examination of explanted liver[J].J Comput Assist Tomogr 2001;25:327-336
3.Kim YK,Kim CS,Chung GH,et al.Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma[J].AJR Am J Roentgenol 2006;186:149-157
4.Sahani DV,Kalva SP.Imaging the liver[J].Oncologist 2004;9:385-397
5.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001;9:324-325
6.周纯武,赵心明,孙伟,刘尚梅.小肝癌的CT表现——31例与病理对照分析[J].中国医学影像技术2001;17:1175-1177
7.Secil M,Obuz F,Altay C,et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma[J].Diagn Interv Radiol 2008;14:200-204
8.Hecht EM,Holland AE,Israel GM,et al.Hepatocellular carcinoma in the cirrhotic liver:gadolinium-enhanced 3D Tl-weighted MR imaging as a stand-alone sequence for diagnosis[J].Radiology 2006;239:438-447
9.Kim SJ,Kim SH,Lee J,et al.Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma[J].In:J Comput Assist Tomogr,2008:379-385
10.Willatt JM,Hussain HK,Adusumilli S,Marrero JA.MR Imaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology 2008;247:311-330
11.Yu JS,Chung JJ,Kim JH,Kim KW.Fat-containing nodules in the cirrhotic liver:chemical shift MRI features and clinical implications[J].AJR Am J Roentgenol 2007;188:1009-1016
12.Murakami T,Kim T,Takamura M,et al.Hypervascular hepatocellular carcinoma:detection with double arterial phase multi-detector row helical CT[J].Radiology 2001;218:763-767
13.Ichikawa T,Kitamura T,Nakajima H,et al.Hypervascular hepatocellular carcinoma:can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver?[J]AJR Am J Roentgeno12002;179:751-758
14.Noguchi Y,Murakami T,Kim T,et al.Detection of hepatocellular carcinoma:comparison of dynamic MR imaging with dynamic double arterial phase helical CT[J].AJR Am J Roentgenol 2003;180:455-460
15.Yanaga Y,Awai K,Nakaura T,et al.Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT[J].AJR Am J Roentgenol 2008;190:1003-1009
16.Furuta A,Ito K,Fujita T,Koike S,Shimizu A,Matsunaga N.Hepatic enhancement in multiphasic contrast-enhanced MDCT:comparison of high-and low-iodine-concentration contrast medium in same patients with chronic liver disease[J].AJR Am J Roentgenol 2004;183:157-162
17.Schima W,Hammerstingl R,Catalano C,et al.Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma:effect of contrast material flow rate[J].AJR Am J Roentgenol 2006;186:1571-1579
18.Holland AE,Hecht EM,Hahn WY,et al.Importance of small (＜or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver:evaluation and comparison with whole explanted liver[J],Radiology 2005;237:938-944
19.Denecke T,Grieser C,Froling V,et al.Multislice computed tomography using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation[J].Transpl Int 2009;22:395-402
20.Li CS,Chen RC,Tu HY,et al.Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography[J].Br J Radiol 2006;79:659-665
21.Roncalli M,Borzio M,Di Tommaso L.Hepatocellular dysplastic nodules[J].Ann ltd Chir 2008;79:81-89
22.Jang HJ,Kim TK,Burns PN,Wilson SR.Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US:comparison with histologic differentiation[J].Radiology 2007;244:898-906
23.Tandon P,Garcia-Tsao G.Prognostic indicators in hepatocellular carcinoma:a systematic review of 72 studies[J].Liver Int 2009;29:502-510
1.Kubota K,Hisa N,Nishikawa T,et al.Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization:comparison of Lipiodol-CT,power Doppler sonography,and dynamic MRI[J].Abdom Imaging 2001;26:184-190
2.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology 2005;42:1208-1236
3.Takayasu K,Arii S,Ikai I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology 2006;131:461-469
4.Palma LD.Diagnostic imaging and interventional therapy of hepatocellular carcinoma[J].Br J Radiol 1998;71:808-818
5.Guan YS,Sun L,Zhou XP,Li X,Zheng XH.Hepatocellular carcinoma treated with interventional procedures:CT and MRI follow-up[J].World J Gastroenterol 2004;10:3543-3548
6.Ebied OM,Federle MP,Carr Bl,et al.Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma[J].Cancer 2003;97:1042-1050
7.De Santis M,Alborino S,Tartoni PL,Torricelli P,Casolo A,Romagnoli R.Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization[J].Eur Radiol 1997;7:10-16
8.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志2001:9:324-325
9.Zangos S,Eichler K,Balzer JO,et al.Large-sized hepatocellular carcinoma(HCC):a neoadjuvant treatment protocol with repetitive transarterial chemoembolization(TACE)before percutaneous MR-guided laser-induced thermotherapy(LITT)[J].Eur Radiol 2007;17:553-563
10.Pleguezuelo M,Marelli L,Misseri M,et al.TACE versus TAE as therapy for hepatocellular carcinoma[J].Expert Rev Anticancer Ther 2008;8:1623-1641
11.Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology 2003;37:429-442
12.Osuga K,Hori S,Hiraishi K,et al.Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres[J].Cardiovasc Intervent Radiol 2008;31:1108-1116
13.邹子扬,赵春梅,李双成,吴飞.海藻酸钠微球血管栓塞剂栓塞治疗原发性肝癌临床研究[J].临床荟萃2006;21:869-872
14.Saccheri S,Lovaria A,Sangiovanni A,et al.Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas[J].J Vasc Interv Radiol 2002;13:995-999
15.Goshima S,Kanematsu M,Matsuo M,et al.Early-enhancing nonneoplastic lesions on gadolinium-enhanced magnetic resonance imaging of the liver following partial hepatectomy[J].J Magn Reson Imaging 2004;20:66-74
16.Ito K,Honjo K,Fujita T,et al.Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma:MRI and pathology[J].J Comput Assist Tomogr 1995;19:198-203
17.张雄彪,王耿,唐玉德,刘树学.Propeller LAVA技术对原发性肝癌MRI的诊断价值[J]实用医技杂志2007;14:1520-1524
18.Chakraborty DP,Winter LH.Free-response methodology:alternate analysis and a new observer-performance experiment[J].Radiology 1990;174:873-881
1.Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis[J].World J Gastroenterol 2008;14:4300-4308
2.Coleman WB.Mechanisms of human hepatocarcinogenesis[J].Curr Mol Med 2003;3:573-588
3.Efremidis SC,Hytiroglou P.The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation[J].Eur Radiol 2002;12:753-764
4.Kudo M.Multistep human hepatocarcinogenesis:correlation of imaging with pathology[J].J Gastroenterol 2009;44 Suppl 19:112-118
5.Krinsky GA,Lee VS.MR imaging of cirrhotic nodules[J].Abdom Imaging 2000;25:471-482
6.Ito K,Mitchell DG.Imaging diagnosis of cirrhosis and chronic hepatitis[J].Intervirology 2004;47:134-143
7.Shah TU,Semelka RC,Pamuklar E,et al.The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI[J].Am J Gastroenterol 2006;101:533-540
8.Terminology of nodular hepatocellular lesions.International Working Party[J].Hepatology 1995;22:983-993
9.Baron RL,Peterson MS.From the RSNA refresher courses:screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging:opportunities and pitfalls[J].Radiographics 2001;21 Spec No:S117-132
10.Lim JH,Kim EY,Lee WJ,et al.Regenerative nodules in liver cirrhosis:findings at CT during arterial portography and CT hepatic arteriography with histopathologic correlation[J].Radiology 1999;210:451-458
11.Freeny PC,Grossholz M,Kaakaji K,Schmiedl UP.Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients:radiologic-histopathologic correlation of explanted livers[J].Abdom Imaging 2003;28:333-346
12.Krinsky GA,Lee VS,Theise ND,et al.Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis:prospective diagnosis with MR imaging and explanation correlation[J].Radiology 2001;219:445-454
13.Theise ND,Schwartz M,Miller C,Thung SN.Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis[J].Hepatology 1992;16:949-955
14.Hytiroglou P,Theise ND.Differential diagnosis of hepatocellular nodular lesions[J].Semin Diagn Pathol 1998;15:285-299
15.Theise ND,Fiel IM,Hytiroglou P,et al.Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein[J].Liver 1995;15:30-34
16.Lim JH,Choi BI.Dysplastic nodules in liver cirrhosis:imaging[J].Abdom Imaging 2002;27:117-128
17.Park YN,Yang CP,Fernandez GJ,Cubukcu O,Thung SN,Theise ND.Neoangiogenesis and sinusoidal“capillarization”in dysplastic nodules of the liver[J].Am J Surg Pathol 1998;22:656-662
18.Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma[J].Lancet 2003;362:1907-1917
19.Taouli B,Goh JS,Lu Y,et al.Growth rate of hepatocellular carcinoma:evaluation with serial computed tomography or magnetic resonance imaging[J].J Comput Assist Tomogr 2005;29:425-429
20.Ikai I,Arii S,Kojiro M,et al.Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J].Cancer 2004;101:796-802
21.Arii S,Yamaoka Y,Futagawa S,et al.Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan.The Liver Cancer Study Group of Japan[J].Hepatology 2000;32:1224-1229
22.Willatt JM,Hussain HK,Adusumilli S,Marrero JA.MR Imaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology 2008;247:311-330
23.Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology 2005;42:1208-1236
24.Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma[J].J Cancer Res Clin Oncol 2004;130:417-422
25.Lencioni R,Cioni D,Della Pina C,Crocetti L,Bartolozzi C.Imaging diagnosis[J].Semin Liver Dis 2005;25:162-170
26.Colli A,Fraquelli M,Casazza G,et al.Accuracy of ultrasonography,spiral CT,magnetic resonance,and alpha-fetoprotein in diagnosing hepatocellular carcinoma:a systematic review[J].Am J Gastroenterol 2006;101:513-523
27.Koito K,Namieno T,Morita K.Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography[J].AJR Am J Roentgenol 1998;170:157-161
28.D'Onofrio M,Faccioli N,Zamboni G,et al.Focal liver lesions in cirrhosis:value of contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels[J].Radiol Med 2008;113:978-991
29.D'Onofrio M,Rozzanigo U,Caffarri S,Zogno A,Procacci C.Contrast-enhanced US of hepatocellular carcinoma[J].Radiol Med 2004;107:293-303
30.Theise ND.Macroregenerative(dysplastic) nodules and hepatocarcinogenesis:theoretical and clinical considerations[J].Semin Liver Dis 1995;15:360-371
31.周纯武,赵心明,孙伟,刘尚梅.小肝癌的CT表现——31例与病理对照分析[J].中国医学影像技术2001;17:1175-1177
32.Noguchi Y,Murakami T,Kim T,et al.Detection of hepatocellular carcinoma:comparison of dynamic MR imaging with dynamic double arterial phase helical CT[J].AJR Am J Roentgenol 2003;180:455-460
33.韩新巍,邢古生,李永东.小肝癌的SCTAP及SCTA表现与血管造影的相关性研究[J].实用医学影像杂志2003;4:4
34.Yamashita Y,Mitsuzaki K,Yi T,et al.Small hepatocellular carcinoma in patients with chronic liver damage:prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver[J].Radiology 1996;200:79-84
35.Oi H,Murakami T,Kim T,Matsushita M,Kishimoto H,Nakamura H.Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma[J].AJR Am J Roentgenol 1996;166:369-374
36.Earls JP,Rofsky NM,DeCorato DR,Krinsky GA,Weinreb JC.Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging:optimization with a test examination and a power injector[J].Radiology 1997;202:268-273
37.Murakami T,Kuroda C,Marukawa T,et al.Regenerating nodules in hepatic cirrhosis:MR findings with pathologic correlation[J].AJR Am J Roentgenol 1990;155:1227-1231
38.Krinsky GA,Israel G.Nondysplastic nodules that are hyperintense on Tl-weighted gradient-echo MR imaging:frequency in cirrhotic patients undergoing transplantation[J].AJR Am J Roentgenol 2003;180:1023-1027
39.Mathieu D,Paret M,Mahfouz AE,et al.Hyperintense benign liver lesions on spin-echo Tl-weighted MR images:pathologic correlations[J].Abdom Imaging 1997;22:410-417
40.Vilgrain V,Lewin M,Vons C,et al.Hepatic nodules in Budd-Chiari syndrome:imaging features[J].Radiology 1999;210:443-450
41.Zhang J,Krinsky GA.Iron-containing nodules of cirrhosis[J].NMR Biomed2004;17:459-464
42.Ito K,Mitchell DG,Gabata T,et al.Hepatocellular carcinoma:association with increased iron deposition in the cirrhotic liver at MR imaging[J].Radiology 1999;212:235-240
43.Earls JP,Theise ND,Weinreb JC,et al.Dysplastic nodules and hepatocellular carcinoma:thin-section MR imaging of explanted cirrhotic livers with pathologic correlation[J].Radiology 1996;201:207-214
44.Krinsky GA,Lee VS,Nguyen MT,et al.Siderotic nodules in the cirrhotic liver at MR imaging with explant correlation:no increased frequency of dysplastic nodules and hepatocellular carcinoma[J].Radiology 2001;218:47-53
45.Sadek AG,Mitchell DG,Siegelman ES,Outwater EK,Matteucci T,Hann HW.Early hepatocellular carcinoma that develops within macroregenerative nodules:growth rate depicted at serial MR imaging[J].Radiology 1995;195:753-756
46.Muramatsu Y,Nawano S,Takayasu K,et al.Early hepatocellular carcinoma:MR imaging[J].Radiology 1991;181:209-213
47.Kim T,Baron RL,Nalesnik MA.Infarcted regenerative nodules in cirrhosis:CT and MR imaging findings with pathologic correlation[J].A JR Am J Roentgenol 2000;175:1121-1125
48.Seki S,Sakaguchi H,Kitada T,et al.Outcomes of dysplastic nodules in human cirrhotic liver:a clinicopathological study[J].Clin Cancer Res 2000;6:3469-3473
49.Hayashi M,Matsui O,Ueda K,et al.Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis:evaluation by CT during intraarterial injection of contrast medium[J].AJRAm J Roentgenol 1999;172:969-976
50.Goshima S,Kanematsu M,Matsuo M,et al.Nodule-in-nodule appearance of hepatocellular carcinomas:comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging[J].JMagn Reson Imaging 2004;20:250-255
51.Kim SJ,Kim SH,Lee J,et al.Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma[J].In:JComput Assist Tomogr,2008:379-385
52.Kelekis NL,Semelka RC,Woosley JT.Malignant lesions of the liver with high signal intensity on Tl-weighted MR images[J].J Magn Reson Imaging 1996;6:291-294
53.Ebara M,Fukuda H,Kojima Y,et al.Small hepatocellular carcinoma:relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchymal].Radiology 1999;210:81-88
54.Hussain HK,Syed I,Nghiem HV,et al.T2-weighted MR imaging in the assessment of cirrhotic liver[J].Radiology 2004;230:637-644
55.Hecht EM,Holland AE,Israel GM,et al.Hepatocellular carcinoma in the cirrhotic liver:gadolinium-enhanced 3D Tl-weighted MR imaging as a stand-alone sequence for diagnosis[J].Radiology 2006;239:438-447
56.Matsui O,Kadoya M,Kameyama T,et al.Benign and malignant nodules in cirrhotic livers:distinction based on blood supply[J].Radiology 1991;178:493-497
57.Matsui O.Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection[J].Intervirology 2004;47:271-276
58.Baron RL,Oliver JH,3rd,Dodd GD,3rd,Nalesnik M,Holbert BL,Carr B.Hepatocellular carcinoma:evaluation with biphasic,contrast-enhanced,helical CT[J].Radiology 1996;199:505-511
59.Ito K,Fujita T,Shimizu A,et al.Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis:differentiating between hypervascular hepatocellular carcinomas and pseudolesions[J].AJR Am J Roentgenol 2004;183:699-705
60.Ito K.Hepatocellular carcinoma:conventional MRI findings including gadolinium-enhanced dynamic imaging[J].Eur J Radiol 2006;58:186-199
61.Marrero JA,Hussain HK,Nghiem HV,Umar R,Fontana RJ,Lok AS.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass[J].Liver Transpl 2005;11:281-289
62.Bolondi L,Gaiani S,Celli N,et al.Characterization of small nodules in cirrhosis by assessment of vascularity:the problem of hypovascular hepatocellular carcinoma[J].Hepatology 2005;42:27-34
63.Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis[J].J Hepatol 2004;40:736-741
64.Takayasu K,Arii S,Ikai I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology 2006;131:461-469
65.Koike Y,Nakagawa K,Shiratori Y,et al.Factors affecting the prognosis of patients with hepatocellular carcinoma invading the portal vein~a retrospective analysis using 952 consecutive HCC patients[J].Hepatogastroenterology 2003;50:2035-2039
66.Aslam Sohaib SA,Teh J,Nargund VH,Lumley JS,Hendry WF,Reznek RH.Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging[J].J Urol 2002;167:1271-1275
67.Park JH,Koh KC,Choi MS,et al.Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma[J].Am J Surg 2006;192:29-33
68.Kim BW,Kim YB,Wang HJ,Kim MW.Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma[J].World J Gastroenterol 2006;12:99-104
69.Matsui O,Kadoya M,Yoshikawa J,et al.Aberrant gastric venous drainage in cirrhotic livers:imaging findings in focal areas of liver parenchymal].Radiology 1995;197:345-349
70.Itai Y,Matsui O.Blood flow and liver imaging[J].Radiology 1997;202:306-314
71.Holland AE,Hecht EM,Hahn WY,et al.Importance of small (＜or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver:evaluation and comparison with whole explanted liver[J].Radiology 2005;237:938-944
72.Peterson MS,Baron RL,Murakami T.Hepatic malignancies:usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging[J].Radiology 1996;201:337-345
73.Kelekis NL,Semelka RC,Worawattanakul S,et al.Hepatocellular carcinoma in North America:a multiinstitutional study of appearance on Tl-weighted,T2-weighted,and serial gadolinium-enhanced gradient-echo images[J].AJR Am J Roentgenol 1998;170:1005-1013
74.Brancatelli G,Baron RL,Peterson MS,Marsh W.Helical CT screening for hepatocellular carcinoma in patients with cirrhosis:frequency and causes of false-positive interpretation[J].AJR Am J Roentgenol 2003;180:1007-1014
75.Shimizu A,Ito K,Koike S,Fujita T,Shimizu K,Matsunaga N.Cirrhosis or chronic hepatitis:evaluation of small (
77.Stigliano R,Burroughs AK.Should we biopsy each liver mass suspicious for HCC before liver transplantation?~no,please don't[J].J Hepatol 2005;43:563-568
78.Marsh JW,Dvorchik I.Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?--yes[J].J Hepatol 2005;43:558-562
79.Chang S,Kim SH,Lim HK,Lee WJ,Choi D,Lim JH.Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma:evaluation of doubling time,frequency,and features on CT[J].AJR Am J Roentgenol 2005;185:400-405
80.Marrero JA,Lok AS.Newer markers for hepatocellular carcinoma[J].Gastroenterology 2004;127:S113-119